Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04445571

Surfactant Administration by Insure or Thin Catheter

This trial evaluates the efficacy and safety of surfactant administration with thin catheter technique together with analgesic premedication in comparison with the established INSURE-strategy. It will provide valuable knowledge to improve clinical methodology and enhance lung protective treatment strategies for preterm infants.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 2 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

To compare two approaches for surfactant administration during CPAP in preterm infants, the INSURE and the LISA technique, using premedication intubation protocols, and investigate aspects of safety, stress and pain, timely administration of the drug, response in oxygenation and pulmonary outcome.

Our study asks whether (P) among infants born <32 weeks' gestation with RDS (I) does surfactant administration with LISA and analgesia premedication (C) versus surfactant administration according to the INSURE protocol (O) improve oxygenation and reduce the rate of respiratory failure and need for intubation and mechanical ventilation (T) within 48 hours of the procedure

Primary outcomes:

  • Positive effect: Oxygenation measured as arterial to alveolar ratio (a/A ratio) at 24 hours post-procedure.
  • Negative effect: Need for mechanical ventilation (MV) within 48 hours post-procedure.

Safety outcomes:

  • Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until surfactant administration
  • Number of tries before successful intubation/placement of catheter
  • Positive pressure ventilation during the procedure - yes/no/duration (minutes)
  • Stress and pain (changes in heart rate, blood pressure and BIIP-scale)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants born before 32 completed weeks of gestation on CPAP, with clinical and radiological signs of RDS and need for surfactant treatment.

Exclusion criteria

  • Infants requiring surfactant as part of delivery room resuscitation are not eligible.

Infants will be excluded from the final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: congenital diaphragmatic hernia; tracheo-oesophageal fistula or cyanotic heart disease.

Treatment and study plan

Thin catheter technique or standard ET-tube for surfactant administration

Procedure

Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.

Primary outcomes

  1. Oxygenation

    Time frame: 24 hours post-procedure

    Arterial to alveolar ratio (a/A ratio)

  2. Mechanical ventilation

    Time frame: 48 hours post-procedure

    Need for intubation and mechanical ventilation (MV)

Secondary outcomes

  1. Duration of ventilatory support

    Time frame: Discharge

    Duration of MV (hours), CPAP (days), Oxygen (days)

  2. Complications

    Time frame: Discharge

    Incidence of air leaks, bronchopulmonary dysplasia, Systemic hypotension, retinopathy, necrotizing entercolitis, intraventricular hemorrhage, persistent duct

  3. Mortality

    Time frame: Discharge

    Death or composite outcome death/BPD

  4. Length of stay

    Time frame: Discharge

    Number of days in NICU and total in neonatal care, including home care

Other outcomes

  1. Delay time

    Time frame: 24 hours

    Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until surfactant administration

  2. Intubation attempts

    Time frame: 24 hours

    Number of tries before successful intubation/placement of catheter

  3. PPV

    Time frame: 24 hours

    Positive pressure ventilation during the procedure - yes/no/duration (minutes)

  4. Stress and pain

    Time frame: 24 hours

    Changes in heart rate, blood pressure and BIIP-scales

Study contacts

Contact information is provided by the study sponsor or research team.

Kajsa Bohlin, MD

CONTACT

[email protected]

+46858580000 ext. 81356

Mats Blennow, MD

CONTACT

[email protected]

+46858580000 ext. 81428

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Acronym: SAINT

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Jun 24, 2020
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.